Company posts 10 per cent growth in profit before tax at Rs 88.5 crores
Alembic Pharmaceuticals reported a nine per cent increase in revenues to Rs 508 crores for the quarter ended March 31, 2015, compared to Rs 465.2 crores in the corresponding quarter last year.
The company posted 10 per cent growth in profit before tax at Rs 88.5 crores for the quarter ended March 31, 2015 against Rs 80.8 crores posted in the corresponding quarter last year. The net profit grew by 15 per cent at Rs 70.3 crores for the quarter ended March 31, 2015 against Rs 61.3 crores in the corresponding quarter last year.
The company reported 11 per cent increase in revenue for year ended March 31, 2015 to Rs 2067.7 crores against Rs 1868.4 crores in the last year. The company reported 16 per cent growth in profit before tax at Rs 359.1 crores for year ended March 31, 2015 against Rs 310.6 crores in the last year. The company also reported 20 per cent growth in net profit for year ended March 31, 2015, Rs 282.9 crores against Rs 235.5 crores in the last year.
The board has recommended dividend on equity shares at Rs 3.50 per share i.e. 175 per cent for 14-15.
The India branded formulations business grew by 16 per cent to Rs 232.1 crores in the quarter against Rs 199.4 crores over the corresponding quarter of the previous year. The India branded formulations business posted sales for year ended March 31, 2015 of Rs 980.8 crores against Rs 850.6 crores with 15 per cent growth over the previous year.
Specialty and acute segments grew by 22 per cent and 11 per cent respectively in current quarter. For the year the growth are 21 per cent and nine per cent respectively for specialty and acute segments.
International generic formulation grew by eight per cent to Rs 147.9 crores in the quarter against Rs 136.6 crores over the corresponding quarter of the previous year.
International generic formulation posted sales for the year ended March 31, 2015 of Rs 518.5 crores against Rs 468.4 crores with 11 per cent growth over the previous year. Two ANDA applications were filed during the quarter, seven ANDA applications for the year ended March 31, 2015, taking cumulative ANDA/ NDA filings of the company to 68. During the quarter one ANDA approval was received, five ANDA approvals for the year ended March 31, 2015, taking cumulative ANDA/ NDA approvals to 37 (including four tentative approvals).
Two DMF applications were filed during the quarter, six DMF applications for the year ended March 31, 2015, taking cumulative DMF filings of the company to 72.
EP News Bureau – Mumbai
Comments are closed.